Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from MAIA Biotechnology, Inc. ( (MAIA) ) is now available.
MAIA Biotechnology, Inc. presented efficacy data from its Phase 2 THIO-101 clinical trial at the 2025 IASLC World Conference on Lung Cancer on September 7, 2025. The trial evaluated THIO in combination with cemiplimab for patients with advanced NSCLC who failed multiple standard treatments, showing improvement in progression-free survival.
The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.
Spark’s Take on MAIA Stock
According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.
MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.
To see Spark’s full report on MAIA stock, click here.
More about MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc. operates in the biotechnology industry, focusing on developing innovative oncology treatments. The company is primarily engaged in advancing therapies for cancer patients, particularly those with limited treatment options, such as advanced non-small cell lung cancer (NSCLC).
Average Trading Volume: 433,791
Technical Sentiment Signal: Sell
Current Market Cap: $50.81M
See more data about MAIA stock on TipRanks’ Stock Analysis page.